EP Patent

EP2698179A1 — Injection device

Assigned to Sanofi Aventis Deutschland GmbH · Expires 2014-02-19 · 12y expired

What this patent protects

The invention refers to an injection device (1) comprising a delivery mechanism for injection of a medicament, preferably through a needle, and an end of dose mechanism comprising a feedback element, wherein the end of dose mechanism is operable to be activated at a position at w…

USPTO Abstract

The invention refers to an injection device (1) comprising a delivery mechanism for injection of a medicament, preferably through a needle, and an end of dose mechanism comprising a feedback element, wherein the end of dose mechanism is operable to be activated at a position at which the delivery mechanism reaches the end of the dose and the end of dose mechanism is further operable to force the feedback element to move into a feedback direction which is opposite or parallel to the activation direction of a release button and/or into the longitudinal direction, wherein the activation direction is preferably a longitudinal direction of the device.

Drugs covered by this patent

Patent Metadata

Patent number
EP2698179A1
Jurisdiction
EP
Classification
—
Expires
2014-02-19
Drug substance claim
No
Drug product claim
No
Assignee
Sanofi Aventis Deutschland GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.